Skip to content
Trouver

Medicine · official US FDA label

LAMIDERM 0,67 POUR CENT

Trolamine (triethanolamine) · émulsion pour application

Want to buy it?

Not in stock in our pharmacies right now. Trouver shows when it is back near you. The reservation pages are in French.

See the pharmacies

This is a US label.

The official US FDA label for triethanolamine (published as TRIETHANOLAMINE SALICYLATE), effective August 6, 2026, describes products sold in the United States. The medicine sold in DR Congo may differ in strength, form or approved uses: ask a pharmacist or a doctor.

Official US FDA label for triethanolamine

Data provided by the U.S. Food and Drug Administration (openFDA), unchanged. The full label on DailyMed.

Uses

INDICATION AND USAGE Salicor™ is indicated for the temporary relief of minor aches and pains of muscles and joints associated with: arthritis, simple backache, muscle strains and sprains, bruises, bursitis, and dysmenorrhea. Salicor™ provides a localized analgesic effect directly at the site of pain, offering convenience and sustained relief compared to cream formulations.

Dosage

US dosage, for products sold in the United States. For a medicine bought in DR Congo, follow its box, its leaflet or your pharmacist.

DOSAGE AND ADMINISTRATION For adults 18 years and older: • Clean and dry the affected area • Locate the tear notch on the edge of the pouch. Tear open at the notch or carefully cut open the pouch with scissors, taking care not to cut the system inside • Remove the transparent release liner before applying Salicor™ to the skin • Apply one Salicor™ to the affected area of pain and leave it in place for 8 to 12 hours • Apply only one Salicor™ at a time • If pain persists, the used Salicor™ may be replaced with a new one for up to 8 to 12 more hours • Always remove and properly dispose of the used Salicor™ before applying a new one • Salicor™ may be cut into smaller sizes with scissors prior to removing the release liner • Safely discard the used Salicor™ (whole or cut pieces) where children and pets cannot access it • Wash hands with soap and water after applying or removing Salicor™ Visual Guide provided below: These highlights do not include all the information needed to use Salicor™ safely and effectively. See full prescribing information for Salicor™ dosing

Warnings and precautions

PRECAUTIONS General If irritation or a burning sensation occurs during application, wash the product off your skin and do not reapply until the irritation subsides. When Salicor™ is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered. Stop use and ask a doctor if • Condition worsens • Symptoms persist for more than 7 days, or symptoms return within a few days after discontinuing use • Redness is present • Irritation develops Hepatic Disease Patients with severe hepatic disease are at greater risk of developing toxic blood concentrations of triethanolamine salicylate because of their inability to metabolize triethanolamine salicylate normally. Allergic Reactions Although rare, allergic reactions to oral or external triethanolamine salicylate may occur. Seek emergency medical help if you experience hives, difficulty breathing, or swelling of the face, lips, tongue, or throat, as these may indicate a serious allergic reaction. Non-intact Skin Although not tested, application to broken or inflamed skin may result in higher blood concentrations of triethanolamine salicylate from increased absorption. Salicor™ is only recommended for use on intact skin. External Heat Sources Placement of external heat sources, such as heating pads or electric blankets, over Salicor™ is not recommended, as this has not been evaluated and may increase plasma triethanolamine salicylate levels. Eye Exposure Although not studied, contact of Salicor™ with the eyes should be avoided based on the findings of severe eye irritation with the use of similar animal products. If eye contact occurs, immediately wash out the eye with water or saline and protect the eye until sensation returns. Information for Patients Methemoglobinemia Inform patients that the use of local anesthetics may cause methemoglobinemia, a serious condition that must be treated promptly. Advise patients or caregivers to stop use and seek immediate medical attention if they or someone in their care experiences the following signs or symptoms: pale, gray, or blue colored skin (cyanosis); headache; rapid heart rate; shortness of breath; lightheadedness; or fatigue.

Where to find it in DR Congo

Not in stock in our pharmacies right now

Stock changes with every sale. Search by substance: a medicine with the same composition may be available.

Composition

SubstanceStrengthATC code
TROLAMINE (triethanolamine)0,670 g / 100 g d'émulsion pour application cutanée—

Sources

  • ●Labels: U.S. Food and Drug Administration, openFDA (public domain). Data provided by the U.S. Food and Drug Administration (openFDA), unchanged. DailyMed.
  • ●English names of substances: RxNorm, U.S. National Library of Medicine.
  • ●Composition: public medicines database of France (BDPM), ANSM, open licence.

Public information, for reference only: it does not replace the advice of a pharmacist or a doctor. Vimpia writes nothing about how to use a medicine and translates nothing: the label is the US FDA's, unchanged; names, composition and authorizations come from the official sources above.